After decades of excruciating pain, a breakthrough sickle cell disease treatment made all the difference for one patient.

In July 2025, Novartis Pharmaceuticals announced a phase III study to assess efficacy and safety of crizanlizumab (5 mg/kg) ...

CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.

A groundbreaking new medical dataset is poised to revolutionize health care in Africa by improving chatbots' understanding of ...